Even though many tumor-associated antigens have been used for diagnosis or target treatment in preclinical experiments, our knowledge about the antigenic epitope of protein antigen related to antibody binding is rare.
As we know, one of the most important mechanisms of action of antibodies for therapies is the antibody-based inhibition function, such as inhibiting key signaling transduction for tumor cell growth. In prostate cancer, antibodies are developed to block the prostate-specific antigen (PSA) binding to a1-antichymotrypsin (ACT). Immune checkpoint antibodies are developed to inhibit the interaction of PD-1 on T cells with PD-L1 on tumor cells. The binding interaction between antibody and epitope peptide inhibits the binding of antigens of homologous origin to the same antibody. This antigen inhibition assay has become a classical method for identifying antigenic epitopes within antigens.
Fig.1 Potential action mechanisms of monoclonal antibody targeting HER2 receptor.1
Creative Biolabs offers custom characterization services of cancer-associated epitopes by synthesizing overlapping peptide libraries derived from an antigen and screening them against antigen-specific antibodies.
Types:
Source of antigen reactive antibodies:
The antigen peptide contains small amino acid residues overlapped with the adjacent peptides.
Specific biological labels are modified to the terminal of the peptide for easy immobilization to the support plate.
For different backgrounds of cancer antigens and different objectives of epitope analysis demands, our experts can design special assays for each client's research. Creative Biolabs is devoted to offering the most reliable and efficient epitope analysis service to help clients develop desired antibodies faster. Please contact us for more detailed information.
For Research Use Only | Not For Clinical Use
Download our brochure